Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1990 Aug;80(8):935–939. doi: 10.2105/ajph.80.8.935

Recent time trends in uterine cancer.

V Persky 1, F Davis 1, R Barrett 1, E Ruby 1, C Sailer 1, P Levy 1
PMCID: PMC1404769  PMID: 2368853

Abstract

Recent trends in corpus uterine cancer incidence rates were explored using 1979-86 data from the Surveillance and End Results Program (SEER); recent trends in hospitalizations for corpus uterine cancer were explored using 1979-86 data from National Hospital Discharge Surveys (NHDS); and recent trends in exogenous hormone use were delineated using data from the 1980, 1981, and 1985 National Ambulatory Medical Care Surveys (NAMCS). Uterine cancer incidence rates using SEER data have continued to decline since 1979. An acceleration in the decline since 1983-84 is suggested in all women and in women with intact uteri ages 45-64. Hospitalizations for uterine cancer have also declined since 1979, with a marked acceleration in the decline since 1983-84 for all women and for women ages 40-79 has increased 22 percent and use of unopposed exogenous estrogens in women of similar age has increased 7 percent, while use of exogenous progesterones have shown much more substantial increases of approximately 700 percent. Possible relationships between trends in exogenous hormone use and incidence rates of corpus uterine cancer are discussed.

Full text

PDF
935

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Centola G. M. Inhibition of endometrial carcinoma cell cultures by a synthetic androgen. Cancer Res. 1985 Dec;45(12 Pt 1):6264–6267. [PubMed] [Google Scholar]
  2. Ewertz M., Jensen O. M. Trends in the incidence of cancer of the corpus uteri in Denmark, 1943-1980. Am J Epidemiol. 1984 May;119(5):725–732. doi: 10.1093/oxfordjournals.aje.a113793. [DOI] [PubMed] [Google Scholar]
  3. Hemminki E., Kennedy D. L., Baum C., McKinlay S. M. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health. 1988 Nov;78(11):1479–1481. doi: 10.2105/ajph.78.11.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hsueh A. J., Peck E. J., Jr, Clark J. H. Control of uterine estrogen receptor levels by progesterone. Endocrinology. 1976 Feb;98(2):438–444. doi: 10.1210/endo-98-2-438. [DOI] [PubMed] [Google Scholar]
  5. Hulka B. S., Chambless L. E., Kaufman D. G., Fowler W. C., Jr, Greenberg B. G. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA. 1982 Jan 22;247(4):475–477. [PubMed] [Google Scholar]
  6. Hulka B. S., Fowler W. C., Jr, Kaufman D. G., Grimson R. C., Greenberg B. G., Hogue C. J., Berger G. S., Pulliam C. C. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol. 1980 May 1;137(1):92–101. doi: 10.1016/0002-9378(80)90391-9. [DOI] [PubMed] [Google Scholar]
  7. Jick H., Walker A. M., Rothman K. J. The epidemic of endometrial cancer: a commentary. Am J Public Health. 1980 Mar;70(3):264–267. doi: 10.2105/ajph.70.3.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kaufman D. W., Shapiro S., Slone D., Rosenberg L., Miettinen O. S., Stolley P. D., Knapp R. C., Leavitt T., Jr, Watring W. G., Rosenshein N. B. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med. 1980 Oct 30;303(18):1045–1047. doi: 10.1056/NEJM198010303031807. [DOI] [PubMed] [Google Scholar]
  9. Marrett L. D., Meigs J. W., Flannery J. T. Trends in the incidence of cancer of the corpus uteri in Connecticut, 1964-1979, in relation to consumption of exogenous estrogens. Am J Epidemiol. 1982 Jul;116(1):57–67. doi: 10.1093/oxfordjournals.aje.a113402. [DOI] [PubMed] [Google Scholar]
  10. Meissner W. A., Sommers S. C. Endometrial changes after prolonged progesterone and testosterone administration to rabbits. Cancer Res. 1966 Mar;26(3):474–478. [PubMed] [Google Scholar]
  11. Persson I. R., Adami H. O., Eklund G., Johansson E. D., Lindberg B. S., Lindgren A. The risk of endometrial neoplasia and treatment with estrogens and estrogen-progestogen combinations. First results of a cohort study after one to four completed years of observation. Acta Obstet Gynecol Scand. 1986;65(3):211–217. doi: 10.3109/00016348609155173. [DOI] [PubMed] [Google Scholar]
  12. Persson I., Adami H. O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989 Jan 21;298(6667):147–151. doi: 10.1136/bmj.298.6667.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Whitehead M. I., Townsend P. T., Pryse-Davies J., Ryder T. A., King R. J. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981 Dec 31;305(27):1599–1605. doi: 10.1056/NEJM198112313052701. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES